Fisher Scientific entered into two separate acquisition agreements with Dharmacon and Oxoid for a total deal value of US$410 M. Fisher acquires Dharmacon for a deal value of US$80 M and Oxoid for a deal value of US$330 M, substantially increasing its product portfolio in RNA interference (RNAi) technology and microbiological culture media and products for testing bacterial contamination.